Mounjaro®
Starting from £179.99/mo
Start journey Learn moreUsing a Mounjaro pen after 30 days in use is not recommended. The Mounjaro SmPC sets a strict 30-day limit once the pen is first used, regardless of how much medication remains inside. After that point, the pen should be disposed of safely — even if doses appear to remain. Mounjaro (tirzepatide) is a prescription-only medicine; the storage rules written into its licence exist for clinical reasons, not convenience. Carrying on past the limit risks injecting medication whose potency and sterility can no longer be guaranteed, and no prescriber would advise it.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
The Mounjaro Summary of Product Characteristics, published on the electronic Medicines Compendium (eMC), is the authoritative source here. Once a Mounjaro KwikPen has been used for the first time, it may be kept at room temperature (below 30°C) or returned to the fridge, but it must be discarded after 30 days regardless of how many doses remain. The NHS medicines information for tirzepatide echoes this: the NHS tirzepatide page directs patients to the leaflet supplied with the medicine for storage and disposal rules, and those rules are the ones the manufacturer has validated through stability testing.
A four-dose pen used weekly fits neatly into the 30-day window. Problems arise when doses are delayed (a missed injection, a week's holiday, an illness) and the final dose falls on day 31 or beyond. That's when patients most often ask whether it's still safe to use. The short answer is: the manufacturer has not validated it beyond 30 days, so you should not use it.
If you want to understand what the SmPC says in full, the Mounjaro SmPC on the eMC is publicly accessible. Section 6.3 covers shelf life and in-use stability. It is worth reading before drawing your own conclusions about leftover doses.
Pharmaceutical stability studies test a medicine under defined conditions for a defined period. Outside that period, the manufacturer makes no claim about potency, sterility or safety. For a subcutaneous injection, that matters more than it would for, say, a tablet. The needle tip has punctured the pen's seal; the solution has been exposed to micro-environmental stresses each time the pen was used. Over time, tirzepatide (a large peptide molecule) is susceptible to degradation.
What that means in practice: an out-of-date pen may deliver a weakened dose, giving you less effect than you'd expect. Or it may have developed particulate contamination. Neither outcome is worth the risk. More on whether it's ever acceptable to use a pen past the 30-day mark is covered separately, but the clinical position is clear.
This is also why counterfeit pens are so dangerous, they carry none of the validated stability data of the genuine licensed product. The MHRA has warned repeatedly about fake weight-loss pens circulating online; even genuine pens stored carelessly or used beyond their validated window present avoidable risk.
Discard the pen in a sealed sharps container, not in household waste, not in a recycling bin. Most community pharmacies will accept a filled sharps container for disposal. Contact your prescriber as soon as you realise a dose has been missed or delayed; they will advise on whether to skip the missed dose and when to take the next one, following the Patient Information Leaflet guidance. Do not double-dose.
The practical move is to build a routine that makes the 30-day limit almost impossible to miss. Keep the pen in the fridge door alongside something you check every week, some people attach a small label showing the discard date the moment they start a new pen. If your treatment schedule has been disrupted and you're unsure what to do next, guidance on what to expect as your treatment progresses can help frame the conversation with your prescriber.
For questions about timing more broadly, this page on dose timing covers what the evidence says about flexibility in your injection schedule. And if you're ever uncertain about how your pen should be stored between doses, our page on Mounjaro storage in the fridge covers refrigeration rules in detail.
The 30-day in-use limit is one of the reasons continuity of supply matters. If your next pen arrives late and you've already had to discard the current one, you face a gap in treatment. That disrupts the steady-state effect that makes tirzepatide work well over time.
Ordering through a GPhC-registered pharmacy that offers same-day dispatch and tracked next-working-day delivery reduces that risk considerably. When a prescription is approved, dispatch happens the same day for orders placed before 12pm Monday to Friday, arriving in plain packaging via DPD the next working day. Speak to our prescribers if you're approaching the end of your current pen and want to make sure your repeat arrives before you need it, every repeat order at nume includes a fresh clinical review, so we'll pick up any questions about your current dose at the same time. You can read more about the consequences of using a Mounjaro pen past its in-use date if you'd like the full picture before your next conversation.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.